ClinicalTrials.gg
CompletedNCT03964493P2_ABSSSIUpdated Dec 1, 2023Results posted

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

A Phase 2 interventional study of TNP-2092 and Vancomycin in Skin and Subcutaneous Tissue Bacterial Infections and Gram-Positive Bacterial Infections, sponsored by TenNor Therapeutics Limited. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by TenNor Therapeutics Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Gram-Positive Bacterial Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Gram-Positive Bacterial Infections · United States.

Enrollment
9th of 19
120 · median 75
Started
2019
the only one that year
Phase 2
8 of 22
none open now
Registered
19th of 22
by date

Among the 22 studies in Gram-Positive Bacterial Infections with a site in United States, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 2, and was the 19th registered.

Gram-Positive Bacterial Infections

58 studies on the registry are indexed under Gram-Positive Bacterial Infections; 6 are open to participants now.

Browse Gram-Positive Bacterial Infections studies →

Open to participants now

None of the 22 studies in Gram-Positive Bacterial Infections with a site in United States is open now. The open studies under Gram-Positive Bacterial Infections, anywhere →

Who these studies take

Of the 2 Gram-Positive Bacterial Infections studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Gram-Positive Bacterial Infections with a site in United States as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.

Read the detailed description

This Phase 2, double-blind, randomized, multicenter, parallel, controlled study is conducted to evaluate safety, tolerability, pharmacokinetics and efficacy of TNP-2092, and vancomycin in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens. The duration of the treatment period is a minimum of 7 days and a maximum of 14 days.

03

Conditions studied

  • Skin and Subcutaneous Tissue Bacterial Infections
  • Gram-Positive Bacterial Infections

Keywords

  • TNP-2092
  • ABSSSI
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects may be included in the study if they meet all of the following inclusion criteria:

    • Males or females, 18 years of age or older;
    • ABSSSI suspected or confirmed to be caused by gram-positive pathogens, including:
    • Cellulitis/erysipelas;
    • Wound infection;
    • Major cutaneous abscess;
    • Lesion with a minimum surface area of 75 cm2;
    • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Subjects will be excluded from the study if any of the following exclusion criteria apply prior to randomization:

    • History or or intolerability to any fluoroquinolone, rifamycin or glycopeptide classes;
    • ABSSSI suspected or confirmed to be caused by pathogens that are resistant to the glycopeptide class;
    • Prior administration of systemic antibacterial therapy within 96 hours before randomization;
    • ABSSSI with suspected or confirmed infection caused by gram-negative or anaerobic organisms;
    • ABSSSI with suspected or confirmed infection caused by fungal, mycobacterial, parasitic, or viral pathogens;
    • Evidence of significant hepatic, hematologic, or immunologic disease;
    • History or evidence of severe renal disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    TNP-2092

    TNP-2092 300 mg intravenous every 12 hours

    Drug: TNP-2092

  • Active comparator
    Vancomycin

    vancomycin 1 g intravenous every 12 hours

    Drug: Vancomycin

Interventions

06

What researchers measure

Primary outcomes

  1. Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population

    Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.

    Time frame: 48 to 72 hours after the first dose of study treatment

  2. Early Clinical Response at the Early Assessment Visit in the Modified Intent-to-Treat (mITT) Population

    Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.

    Time frame: 48 to 72 hours after the first dose of study treatment

  3. Early Clinical Response at the Early Assessment Visit in the Micro-Intent-to-Treat (Micro-ITT) Population

    Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.

    Time frame: 48 to 72 hours after the first dose of study treatment

Secondary outcomes

  1. Investigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the mITT Population

    At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

    Time frame: 7 to 14 days after the end of study treatment

  2. Investigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the Micro-ITT Population

    At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

    Time frame: 7 to 14 days after the end of study treatment

  3. Investigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the mITT Population

    At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

    Time frame: After a minimum of 7 days up to 14 days of study treatment

  4. Investigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the Micro-ITT Population

    At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

    Time frame: After a minimum of 7 days up to 14 days of study treatment

  5. AUC0-12h After First Infusion

    Partial area under the concentration versus time curve from time zero to time 12 hours.

    Time frame: 0 to 12 hours post-dose

  6. AUC0-12h After Last Infusion

    Partial area under the concentration versus time curve from time zero to time 12 hours

    Time frame: 0 to 12 hours post-dose

  7. Cmax After Last Infusion

    Maximum observed concentration

    Time frame: 57 to 60 minutes, 1.5 to 3 hours, 4 to 6 hours, 12 hours, after the last infusion

  8. Cmax After First Infusion

    Maximum observed concentration

    Time frame: 57 to 60 minutes, 1.5 to 3 hours, 4 to 6 hours, 12 hours, after the first infusion

07

Results

Posted Dec 1, 2023

Participant flow

Participant flow — Overall Study
MilestoneTNP-2092Vancomycin
Started8040
Completed6335
Not completed175
Withdrew: Withdrawal by subject41
Withdrew: Lost to follow-up134

Outcome measures

PrimaryEarly Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population

Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.

Time frame:
48 to 72 hours after the first dose of study treatment
Reported as:
Count of participants · Participants
Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population
ParticipantsTNP-2092Vancomycin
Responder6127
Nonresponder43
Indeterminate1510
PrimaryEarly Clinical Response at the Early Assessment Visit in the Modified Intent-to-Treat (mITT) Population

Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.

Time frame:
48 to 72 hours after the first dose of study treatment
Reported as:
Count of participants · Participants
Early Clinical Response at the Early Assessment Visit in the Modified Intent-to-Treat (mITT) Population
ParticipantsTNP-2092Vancomycin
Responder6027
Nonresponder43
Indeterminate1410
PrimaryEarly Clinical Response at the Early Assessment Visit in the Micro-Intent-to-Treat (Micro-ITT) Population

Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.

Time frame:
48 to 72 hours after the first dose of study treatment
Reported as:
Count of participants · Participants
Early Clinical Response at the Early Assessment Visit in the Micro-Intent-to-Treat (Micro-ITT) Population
ParticipantsTNP-2092Vancomycin
Responder4119
Nonresponder32
Indeterminate78
SecondaryInvestigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the mITT Population

At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

Time frame:
7 to 14 days after the end of study treatment
Reported as:
Count of participants · Participants
Investigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the mITT Population
ParticipantsTNP-2092Vancomycin
Success6231
Failure23
Indeterminate146
SecondaryInvestigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the Micro-ITT Population

At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

Time frame:
7 to 14 days after the end of study treatment
Reported as:
Count of participants · Participants
Investigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the Micro-ITT Population
ParticipantsTNP-2092Vancomycin
Success4023
Failure21
Indeterminate95
SecondaryInvestigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the mITT Population

At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

Time frame:
After a minimum of 7 days up to 14 days of study treatment
Reported as:
Count of participants · Participants
Investigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the mITT Population
ParticipantsTNP-2092Vancomycin
Success6831
Failure23
Indeterminate86
SecondaryInvestigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the Micro-ITT Population

At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).

Time frame:
After a minimum of 7 days up to 14 days of study treatment
Reported as:
Count of participants · Participants
Investigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the Micro-ITT Population
ParticipantsTNP-2092Vancomycin
Success4523
Failure21
Indeterminate45
SecondaryAUC0-12h After First Infusion

Partial area under the concentration versus time curve from time zero to time 12 hours.

Time frame:
0 to 12 hours post-dose
Reported as:
Mean · h*ng/mL
AUC0-12h After First Infusion
h*ng/mLTNP-2092
AUC0-12h After First Infusion135000 ± 38200
SecondaryAUC0-12h After Last Infusion

Partial area under the concentration versus time curve from time zero to time 12 hours

Time frame:
0 to 12 hours post-dose
Reported as:
Mean · h*ng/mL
AUC0-12h After Last Infusion
h*ng/mLTNP-2092
AUC0-12h After Last Infusion159000 ± 74200
SecondaryCmax After Last Infusion

Maximum observed concentration

Time frame:
57 to 60 minutes, 1.5 to 3 hours, 4 to 6 hours, 12 hours, after the last infusion
Reported as:
Mean · ng/mL
Cmax After Last Infusion
ng/mLTNP-2092
Cmax After Last Infusion38500 ± 13400
SecondaryCmax After First Infusion

Maximum observed concentration

Time frame:
57 to 60 minutes, 1.5 to 3 hours, 4 to 6 hours, 12 hours, after the first infusion
Reported as:
Mean · ng/mL
Cmax After First Infusion
ng/mLTNP-2092
Cmax After First Infusion37500 ± 13500

Adverse events

Collected over Adverse events were assessed from the first day of study treatment (day 1) to long-term follow-up visit(20 to 25 days after end of treatment), A Serious Adverse event (SAE) will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNP-20920/78 (0%)1/78 (1.3%)27/78 (34.6%)
Vancomycin0/39 (0%)2/39 (5.1%)11/39 (28.2%)
Most frequent serious events
Most frequent serious events
EventTNP-2092Vancomycin
mental status changesPsychiatric disorders0/781/39
left upper extremity abscess,dehydrationSkin and subcutaneous tissue disorders0/781/39
MRSA bacteremia and worsening cellulitisSkin and subcutaneous tissue disorders1/780/39
Most frequent other events
Most frequent other events
EventTNP-2092Vancomycin
NauseaGastrointestinal disorders12/782/39
CellulitisSkin and subcutaneous tissue disorders7/785/39
VomitingGastrointestinal disorders6/782/39
Wound infectionInfections and infestations2/782/39

Baseline characteristics

Age, Continuous
Age, Continuous(years)TNP-2092VancomycinTotal
Mean41.4 ± 11.7242.7 ± 13.1641.9 ± 12.18
Sex: Female, Male
Sex: Female, Male(Participants)TNP-2092VancomycinTotal
Female191433
Male612687
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TNP-2092VancomycinTotal
Hispanic or Latino321749
Not Hispanic or Latino482371
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNP-2092VancomycinTotal
American Indian or Alaska Native134
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American549
White7032102
More than one race000
Unknown or Not Reported415
Height
Height(cm)TNP-2092VancomycinTotal
Mean173.5 ± 9.46170.5 ± 8.32172.5 ± 9.17
Body mass index
Body mass index(kg/m^2)TNP-2092VancomycinTotal
Mean24.1 ± 2.9824.8 ± 3.4724.4 ± 3.15
Weight
Weight(kg)TNP-2092VancomycinTotal
Mean72.8 ± 11.8172.7 ± 14.4372.8 ± 12.68
08

Study locations

1 site
  • eStudy Site
    San Diego, California 92120, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Sep 2020, 17 months.

Results were first posted in Dec 2023, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2019
First posted
May 28, 2019
StartActual
Apr 20, 2019
Primary completionActual
Sep 28, 2020
CompletionActual
Sep 28, 2020
Results first posted
Dec 1, 2023
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03964493
Lead sponsor
TenNor Therapeutics Limited
Responsible party
Sponsor
First posted
May 28, 2019
Start date
Apr 20, 2019
Primary completion
Sep 28, 2020
Completion
Sep 28, 2020
Results posted
Dec 1, 2023
Last update
Dec 1, 2023

Study contacts

TenNor Clinical Trials
study director · TenNor

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNP-2092

Start the discussion